IP Library Granted Patent US 12,661,516
Granted Patent B2
US 12,661,516 · App. 18/747,310 · Granted Jun 23, 2026

Treatment of neurodegenerative disease with high frequency stimulation, and associated systems and methods

Inventors: James R. Thacker (Homer, AK); Kerry Bradley (Glendale, CA); Dongchul Lee (Agua Dulce, CA)
Assignee: Nevro Corporation
A61N1/36171A61N1/06A61N1/36062A61N1/36082A61N1/36175
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,661,516
App. No.
18/747,310
Granted
Jun 23, 2026
Kind
B2
Abstract

Systems and methods for treating neurodegenerative disorders with high frequency stimulation are disclosed. A representative method for treating a patient includes applying an electrical signal to the patient via a treatment system that includes a signal delivery element positioned at or within a white matter of the patient's brain, spinal cord, or both, the electrical signal having a frequency of from about 1.5 kHz to about 100 kHz.

Claims (30)

1 . A method for treating a neurodegenerative disease in a patient, the method comprising:

programming a signal generator to deliver an electrical signal to the patient via a signal delivery element positioned at or within white matter of the patient's brain,

wherein the electrical signal has a frequency within a frequency range of from about 5 kHz to about 100 kHz, and

wherein the electrical signal addresses the patient's neurodegenerative disease.

2 . The method of claim 1 wherein the electrical signal modulates one or more glial cells present in the white matter at or proximate the signal delivery element.

3 . The method of claim 2 wherein the one or more glial cells include one or more astrocytes.

4 . The method of claim 1 wherein the electrical signal has a frequency of at least 50 KHz.

5 . The method of claim 1 wherein the electrical signal has a pulse width in a pulse width range of from about 10 microseconds to about 30 microseconds.

6 . The method of claim 1 wherein the electrical signal does not induce paresthesia in the patient.

7 . The method of claim 1 wherein the electrical signal modulates ion-pump activity of one or more neurons and/or glial cells within the white matter of the brain without the use of ATP.

8 . The method of claim 1 wherein the neurodegenerative disease includes Parkinson's disease.

9 . The method of claim 1 wherein the signal delivery element is positioned at or proximate a degenerative lesion within the white matter of the patient's brain.

10 . The method of claim 9 wherein programming the signal generator is performed at least partially in response to an indication of the degenerative lesion.

11 . A method for treating a neurodegenerative disease in a patient, the method comprising:

programming a signal generator to deliver an electrical signal to one or more glial cells of the patient via a signal delivery element positioned at or within white matter of the patient's brain,

wherein the electrical signal has a frequency within a frequency range of from about 5 kHz to about 100 kHz, and

wherein the electrical signal modulates ion-pump activity of the one or more glial cells within the white matter of the brain without the use of ATP to address the neurodegenerative disease of the patient.

12 . The method of claim 11 wherein the one or more glial cells include one or more astrocytes.

13 . The method of claim 11 wherein the frequency is at least 50 KHz.

14 . A system for treating a neurodegenerative disease in a patient, the system comprising:

a signal delivery element configured to be positioned at or within white matter of the patient's brain; and

a signal generator programmed with instructions that, when executed, cause the signal generator to deliver an electrical signal to the white matter of the patient's brain via the signal delivery element, wherein the electrical signal has a frequency within a frequency range of from about 5 kHz to about 100 kHz, and wherein the electrical signal addresses the patient's neurodegenerative disease.

15 . The system of claim 14 wherein the signal delivery element is configured to be positioned proximate one or more glial cells within the white matter such that the electrical signal modulates the one or more glial cells.

16 . The system of claim 15 wherein the one or more glial cells include one or more astrocytes.

17 . The system of claim 14 wherein the signal delivery element is configured to be positioned at or proximate a degenerative lesion within the white matter of the patient's brain.

18 . The system of claim 14 wherein the electrical signal has a frequency of at least 50 kHz.

19 . The system of claim 14 wherein the electrical signal has a pulse width in a pulse width range of from about 10 microseconds to about 30 microseconds.

20 . The system of claim 14 wherein the electrical signal does not induce paresthesia in the patient.

21 . The system of claim 14 wherein, when administered, the electrical signal modulates ion-pump activity of one or more neurons and/or glial cells within the white matter of the brain without the use of ATP.

22 . The system of claim 14 wherein the neurodegenerative disease includes Parkinson's disease.